Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Esperion Therapeutics Inc. maintains a presence in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This matter is assigned to 1 distinct examiner and 1 distinct art unit. The current prosecution activity is concentrated, suggesting a specific focus within the pharmaceutical sector where the workload is contained within a lone administrative path. This concentrated activity indicates that the company's current patenting efforts are focused on a specific pharmaceutical development rather than a broad array of filings.
HUTTER, GILLIAN A is the busiest examiner for the company. This examiner is handling 1 busiest examiner pending office action. As this examiner is the sole individual currently reviewing the company's active patent applications, strategy for this portfolio involves navigating the specific requirements of this individual and the corresponding art unit. The company's current legal standing at the patent office is defined by this single interaction, making the examiner's specific prosecution style a critical factor for success. Given the complexity of the biotechnology sector, the company's strategy must be precisely calibrated to the specific review style and technical requirements of this individual examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.5% | +46.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17271045 | METHODS FOR REDUCING THE RISK OF DIABETES IN PATIENTS BEING TREATED FOR HIGH CHOLESTEROL-RELATED ILLNESSES | HUTTER, GILLIAN A | 57d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17271045 | METHODS FOR REDUCING THE RISK OF DIABETES IN PATIENTS BEING TREATED FOR HIGH CHOLESTEROL-RELATED ILLNESSES | HUTTER, GILLIAN A | 1625 | §102 | Non-Final OA | 57d | Pending | Feb 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial